[Ip-health] Article on Patent Pooling to Address the COVID-19 Pandemic

Frederick Abbott FAbbott at law.fsu.edu
Wed Jul 29 14:02:01 PDT 2020


Jerry Reichman and I have prepared the linked article on mandatory patent pooling at the global, regional and/or national level to address supply and demand for vaccines, treatments, diagnostics and medical equipment to address the COVID-19 pandemic. We hope you may find it of interest. Fred Abbott

Facilitating Access to Cross-Border Supplies of Patented Pharmaceuticals: The Case of the COVID-19 Pandemic

Frederick M. Abbott  and Jerome H. Reichman

July 20, 2020 - Journal of International Economic Law (Oxford)(forthcoming Vol. 23, Issue 3, Sept. 2020)

Available for download on SSRN: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3656725 or
http://dx.doi.org/10.2139/ssrn.3656725<https://dx.doi.org/10.2139/ssrn.3656725>

Abstract

The COVID-19 pandemic has brought into stark relief the gaps in global preparedness to address widespread outbreaks of deadly viral infections. This article proposes legal mechanisms for addressing critical issues facing the international community in terms of providing equitable access to vaccines, treatments, diagnostics and medical equipment. On the supply side, the authors propose the establishment of mandatory patent pools (‘Licensing Facilities’) on a global or regional, or even national basis, depending upon the degree of cooperation that may be achieved. The authors also discuss the importance of creating shared production facilities. On the demand side, the authors propose the establishment of Regional Pharmaceutical Supply Centers for the collective procurement of products, and the need to coordinate the issuance of necessary compulsory licenses for production and/or importation, depending on relevant circumstances. The authors envisage that centralized coordination by Regional Pharmaceutical Supply Centers should assist in overcoming difficulties individual countries may encounter in addressing administrative and technical issues in procuring supplies, as well as creating improved bargaining leverage with potential suppliers. The authors finally address the problem created by the decision of various High-Income Countries (HICs) to ‘opt out’ as eligible importing countries under the WTO TRIPS Agreement Article 31bis amendment that addresses the predominant export of pharmaceutical products under compulsory licenses.

Prof. Fred Abbott
Florida State Univ. College of Law

Prof. Jerry Reichman
Duke University School of Law




More information about the Ip-health mailing list